Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription Articles published in Clin Res Hepatol Gastroenterol Retrieve available abstracts of 300 articles: HTML format

Single Articles

May 2024
1. ZHU X, Zeng C, Yu B
   White adipose tissue in metabolic associated fatty liver disease.
   Clin Res Hepatol Gastroenterol. 2024;48:102336.
   PubMed     Abstract available
   
   
   
2. ABBASSI N, Bourrahouat A, Bedoya EC, Pagan C, et al
   Phenotype and molecular characterization of Wilson's disease in Morocco.
   Clin Res Hepatol Gastroenterol. 2024;48:102335.
   PubMed     Abstract available
   
   
   
3. WONG SH, Ng HI, Liu Y, Yu HH, et al
   Endoscopic submucosal dissection for early esophageal squamous cell carcinoma after ligation and sclerotherapy of esophageal and gastric varices.
   Clin Res Hepatol Gastroenterol. 2024;48:102339.
   PubMed     Abstract available
   
   
   
4. FULBERT M, El Amrani M, Baillet C, Lecolle K, et al
   Sarcopenia does not affect liver regeneration and postoperative course after a major hepatectomy. A prospective study on 125 patients using CT volumetry and HIDA scintigraphy.
   Clin Res Hepatol Gastroenterol. 2024;48:102332.
   PubMed     Abstract available
   
   
   
5. LI R, Sarin S
   The smoker's paradox in transjugular intrahepatic portosystemic shunt procedure: A national inpatient sample analysis from 2015 to 2020.
   Clin Res Hepatol Gastroenterol. 2024;48:102323.
   PubMed     Abstract available
   
   
   
6. LIANG Y, Li J, Zhang Z, Jiang T, et al
   Extrahepatic conditions of primary biliary cholangitis: A systematic review and meta-analysis of prevalence and risk.
   Clin Res Hepatol Gastroenterol. 2024;48:102321.
   PubMed     Abstract available
   
   
   April 2024
7. PATEL K, Twohig P, Peeraphatdit T, Stohs EJ, et al
   Outcomes and factors associated with cryptococcal disease among cirrhotics: A study of the national inpatient sample 2005 to 2014.
   Clin Res Hepatol Gastroenterol. 2024;48:102337.
   PubMed     Abstract available
   
   
   
8. LI Y, Guo Y, Tan S
   Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease.
   Clin Res Hepatol Gastroenterol. 2024;48:102320.
   PubMed     Abstract available
   
   
   
9. ORUC M, Gedik ME, Uner M, Ulug E, et al
   Effectiveness of metformin for the reversal of cold-ischemia-induced damage in hepatosteatosis.
   Clin Res Hepatol Gastroenterol. 2024;48:102314.
   PubMed     Abstract available
   
   
   
10. JI J, Zhang Z, Hou Z, Qiu G, et al
    Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102313.
    PubMed     Abstract available
    
    
    March 2024
11. NDHLOVU E, Zhang BX, Chen XP, Zhu P, et al
    Thermal ablation for hepatic tumors in high-risk locations.
    Clin Res Hepatol Gastroenterol. 2024;48:102300.
    PubMed     Abstract available
    
    
    
12. LI B, Ren ZW, Zhang C, Yu XX, et al
    Computed tomography-guided percutaneous cryoablation and microwave ablation in the treatment of perivascular hepatocellular carcinoma: A comparative study with propensity score matching.
    Clin Res Hepatol Gastroenterol. 2024;48:102298.
    PubMed     Abstract available
    
    
    
13. RAN D, Xin C, Ma Y, Lu Y, et al
    Increased risk of colorectal adenomas with metabolic-associated fatty liver disease components.
    Clin Res Hepatol Gastroenterol. 2024;48:102302.
    PubMed     Abstract available
    
    
    
14. CHEN F, Chen C, Zhang Y, Jiang L, et al
    Bilateral optic atrophy in Wilson disease: A case report and literature review.
    Clin Res Hepatol Gastroenterol. 2024;48:102299.
    PubMed     Abstract available
    
    
    
15. AN Y, Xia Y, Wang Z, Jin GZ, et al
    Clinical significance of ribosome production factor 2 homolog in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2024;48:102289.
    PubMed     Abstract available
    
    
    
16. HAYAT HMS, Naeem H
    Aspirin for non alcoholic fatty liver disease: Promising but inconclusive-A letter to the editor.
    Clin Res Hepatol Gastroenterol. 2024;48:102286.
    PubMed    
    
    
    
17. HOOSHMAND GHARABAGH L, Shargh A, Mohammad Hosseini Azar MR, Esmaeili A, et al
    Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102279.
    PubMed     Abstract available
    
    
    February 2024
18. GUO J, Shi L, Sun Y
    Association of composite dietary antioxidant index and muscle mass in individuals with metabolic associated fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102284.
    PubMed     Abstract available
    
    
    
19. HE Q, Xiong Y, Xia P, Yang X, et al
    Predicting cancer-specific mortality in T1/2 hepatocellular carcinoma after radiofrequency ablation by competing risk nomogram: A population-based analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102283.
    PubMed     Abstract available
    
    
    
20. MEJAIT A, Roux C, Soret M, Larrey E, et al
    Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival.
    Clin Res Hepatol Gastroenterol. 2024;48:102282.
    PubMed     Abstract available
    
    
    
21. QI X, Liu L
    The regulatory effect of lncRNA LINC00943 on the progression of hepatocellular carcinoma and its relationship with clinicopathological features.
    Clin Res Hepatol Gastroenterol. 2024;48:102273.
    PubMed     Abstract available
    
    
    
22. XIE C, Liu K, Xie Y, Liu S, et al
    Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102264.
    PubMed     Abstract available
    
    
    
23. OBADIA MA, Woimant F, Tuppin P, Debray D, et al
    Reply to "Epidemiology, treatment and burden of Wilson disease in France: A 10-year analysis of the National health insurance database".
    Clin Res Hepatol Gastroenterol. 2024;48:102265.
    PubMed    
    
    
    January 2024
24. KUMAR J, Mohsin S, Hasan M, Bilal AR, et al
    Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102261.
    PubMed     Abstract available
    
    
    
25. KUMAR MS
    Paneth cell: The missing link between obesity, MASH and portal hypertension.
    Clin Res Hepatol Gastroenterol. 2024;48:102259.
    PubMed     Abstract available
    
    
    
26. BAEK KW, Won JH, Xiang YY, Woo DK, et al
    Exercise intensity impacts the improvement of metabolic dysfunction-associated steatotic liver disease via variations of monoacylglycerol O-acyltransferase 1 expression.
    Clin Res Hepatol Gastroenterol. 2024;48:102263.
    PubMed     Abstract available
    
    
    
27. CHEVAL M, Latrasse M, Tran Ba S, Robbe G, et al
    Extensive cortical and thalamic FLAIR hypersignals in a patient with suspected hepatic encephalopathy.
    Clin Res Hepatol Gastroenterol. 2024;48:102258.
    PubMed    
    
    
    
28. SEXTON F, Shanahan W, Ryan JD
    Xanthoma striatum palmare: Getting a handle on hyperlipidaemia in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102255.
    PubMed    
    
    
    December 2023
29. THABUT D, Roux J, Simon-Sultanik P, Tamberou C, et al
    Population characteristics, healthcare pathways and outcomes of patients with cirrhosis hospitalized with overt hepatic encephalopathy in France: a study of the French Hospital-Discharge Database.
    Clin Res Hepatol Gastroenterol. 2023 Dec 26:102274.
    PubMed     Abstract available
    
    
    
30. LASSAILLY G, Ningarhari M, Dumortier J, Lafforgue C, et al
    Good outcome of liver transplantation in patients with pre-existing renal cell carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;48:102266.
    PubMed     Abstract available
    
    
    
31. JIANG J, Hu Y, Fang D, Luo J, et al
    Glutamine synthetase and hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102248.
    PubMed     Abstract available
    
    
    
32. ZHANG X, Li X, Xiong X
    Applying proteomics in metabolic dysfunction-associated steatotic liver disease: From mechanism to biomarkers.
    Clin Res Hepatol Gastroenterol. 2023;47:102230.
    PubMed     Abstract available
    
    
    
33. JANG H, Han N, Staatz CE, Kwak JH, et al
    Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102227.
    PubMed     Abstract available
    
    
    
34. TAMILMANI P, Sathibabu Uddandrao VV, Chandrasekaran P, Saravanan G, et al
    Linalool attenuates lipid accumulation and oxidative stress in metabolic dysfunction-associated steatotic liver disease via Sirt1/Akt/PPRA-alpha/AMPK and Nrf-2/HO-1 signaling pathways.
    Clin Res Hepatol Gastroenterol. 2023;47:102231.
    PubMed     Abstract available
    
    
    
35. PEI E, Wang H, Li Z, Xie X, et al
    Endoplasmic reticulum stress inhibitor may substitute for sleeve gastrectomy to alleviate metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102229.
    PubMed     Abstract available
    
    
    
36. JIANG R, Zhou Y, Han L, Hong Z, et al
    Serum vitamin D is associated with ultrasound-defined hepatic fibrosis.
    Clin Res Hepatol Gastroenterol. 2023;47:102228.
    PubMed     Abstract available
    
    
    
37. DONATI A, Henrion J, Regnier M, Deltenre P, et al
    Abstinence is associated with better outcomes in patients with alcohol-related hepatocellular carcinoma: Results of an observational study.
    Clin Res Hepatol Gastroenterol. 2023;47:102225.
    PubMed     Abstract available
    
    
    November 2023
38. ALLAIRE M, Roux C, Akhavan S, Lebray P, et al
    Difficulties in assessing portal hypertension in case of HVB-HVD co infection.
    Clin Res Hepatol Gastroenterol. 2023;47:102213.
    PubMed    
    
    
    
39. MUTANEN A, Pakarinen MP
    Featuring molecular regulation of bile acid homeostasis in pediatric short bowel syndrome.
    Clin Res Hepatol Gastroenterol. 2023;47:102220.
    PubMed     Abstract available
    
    
    October 2023
40. DENG K, Yang F, Liu X, Deng M, et al
    Adult Kasabach-Merritt syndrome secondary to hepatic angiosarcoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102211.
    PubMed    
    
    
    
41. CHAIBI S, Larrey E, Couty JP, Sultanik P, et al
    Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC.
    Clin Res Hepatol Gastroenterol. 2023;47:102199.
    PubMed     Abstract available
    
    
    
42. DUMONT C, Lanthier N, Dahlqvist G
    Fibrosis and steatosis of the liver graft: Are non-invasive tests useful? A short review.
    Clin Res Hepatol Gastroenterol. 2023;47:102194.
    PubMed     Abstract available
    
    
    
43. DI GIORGIO A, Sciveres M, Fuoti M, Sonzogni A, et al
    Treatment with an ileal bile acid transporter inhibitor in patients with TJP2 deficiency.
    Clin Res Hepatol Gastroenterol. 2023;47:102185.
    PubMed     Abstract available
    
    
    
44. BOILLOT O, Guillaud O, Wischlen E, Ruiz M, et al
    Determinants of early surgical complications after pediatric liver transplantation: A single center/single surgeon experience over 20 years.
    Clin Res Hepatol Gastroenterol. 2023;47:102222.
    PubMed     Abstract available
    
    
    August 2023
45. LU M, Zhu M, Li H, Wang Q, et al
    Factors associated with discordance in the assessment of fibrosis stage between transient elastography and liver biopsy in NAFLD patients.
    Clin Res Hepatol Gastroenterol. 2023;47:102183.
    PubMed     Abstract available
    
    
    
46. TANG Y, Zhong H, Wang Y, Wu J, et al
    Efficacy of microwave ablation versus radiofrequency ablation in the treatment of colorectal liver metastases: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102182.
    PubMed     Abstract available
    
    
    
47. MAMANDIPOOR B, Wernly S, Semmler G, Flamm M, et al
    Machine learning models predict liver steatosis but not liver fibrosis in a prospective cohort study.
    Clin Res Hepatol Gastroenterol. 2023;47:102181.
    PubMed     Abstract available
    
    
    
48. CALLERI A, Alessandria C
    Renal damage in Hepatorenal Syndrome: A still unsolved issue.
    Clin Res Hepatol Gastroenterol. 2023;47:102178.
    PubMed     Abstract available
    
    
    
49. BANDYOPADHYAY S, Samajdar SS, Das S
    Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102174.
    PubMed     Abstract available
    
    
    
50. GUO B, Zhou Y, Liu Z, Chen Q, et al
    TACE plus PD-1 successfully achieves conversion therapy for unresectable HCC with multiple macrovascular invasion: Case report.
    Clin Res Hepatol Gastroenterol. 2023;47:102169.
    PubMed    
    
    
    
51. PENA LC, Couto CA, Correa BHM, Ferrua LFQ, et al
    Poor cardiorespiratory fitness may be an indicator of more severe liver inflammation in non-alcoholic fatty liver disease patients.
    Clin Res Hepatol Gastroenterol. 2023;47:102163.
    PubMed     Abstract available
    
    
    
52. LI ZX, Zhang QF, Huang JM, Huang SJ, et al
    Safety and efficacy of postoperative adjuvant therapy with atezolizumab and bevacizumab after radical resection of hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102165.
    PubMed     Abstract available
    
    
    
53. ISMAIEL A, Hosiny BE, Ismaiel M, Leucuta DC, et al
    Waist to height ratio in nonalcoholic fatty liver disease - Systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102160.
    PubMed     Abstract available
    
    
    
54. WAN W, Zhang H, Ji T, Zhang L, et al
    Optimal treatment strategy for recurrent hepatocellular carcinoma based on recurrence time and tumor size: A propensity score matching study.
    Clin Res Hepatol Gastroenterol. 2023;47:102157.
    PubMed     Abstract available
    
    
    
55. ALOYSIUS MM, Iskander P, Ahmed K, Asija U, et al
    Fibrolamellar hepatocellular carcinoma: An epidemiologic and 5-year cancer survival assessment based off SEER data.
    Clin Res Hepatol Gastroenterol. 2023;47:102162.
    PubMed     Abstract available
    
    
    
56. YANG Y, Li X, Zhao X, Liu Y, et al
    Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study.
    Clin Res Hepatol Gastroenterol. 2023;47:102150.
    PubMed     Abstract available
    
    
    
57. LU Y, Liang L, Lu WF, Cheng J, et al
    The prognosis of elderly patients with hepatocellular carcinoma after curative hepatectomy a multicenter competing risk analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102147.
    PubMed     Abstract available
    
    
    
58. XU J, Shao R, Zhang X, Yao D, et al
    Serum cell division cycle 42 in advanced hepatocellular carcinoma patients: Linkage with clinical characteristics and immune checkpoint inhibitor-related treatment outcomes.
    Clin Res Hepatol Gastroenterol. 2023;47:102149.
    PubMed     Abstract available
    
    
    June 2023
59. WANG X, Xu GH, Yu J, Li H, et al
    When cirrhosis meets paroxysmal nocturnal hemoglobinuria: What kind of "fireworks" scenario will occur?
    Clin Res Hepatol Gastroenterol. 2023;47:102173.
    PubMed    
    
    
    
60. GIUDICELLI H, Roux C, Monsel A, Conti F, et al
    Successful advanced hepatocellular carcinoma downstaging with atezolizumab-Bevacizumab and radioembolization before liver transplantation.
    Clin Res Hepatol Gastroenterol. 2023 Jun 19:102167.
    PubMed    
    
    
    May 2023
61. WISCHLEN E, Laverdure N, Erard D, Rohmer B, et al
    Iterative antibody-induced bile salt export pump deficiency after successive liver transplantations successfully treated with plasmapheresis and rituximab.
    Clin Res Hepatol Gastroenterol. 2023;47:102139.
    PubMed     Abstract available
    
    
    
62. MATHURIN P, de Zelicourt M, Laurendeau C, Dhaoui M, et al
    Treatment patterns, risk factors and outcomes for patients with newly diagnosed hepatocellular carcinoma in France: A retrospective database analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102124.
    PubMed     Abstract available
    
    
    
63. RAVAIOLI F, Berger A, Farcau O, Colecchia A, et al
    Individual and population screening of varices needing treatment by a simple, safe and accurate test.
    Clin Res Hepatol Gastroenterol. 2023;47:102123.
    PubMed     Abstract available
    
    
    
64. MALKANI KV, Jesudian AB, Luo JJ, Schonfeld EA, et al
    Noncirrhotic portal hypertension in primary biliary cholangitis with coexisting CREST syndrome.
    Clin Res Hepatol Gastroenterol. 2023;47:102114.
    PubMed     Abstract available
    
    
    
65. HAMEED I, Hayat J, Marsia S, Samad SA, et al
    Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102111.
    PubMed     Abstract available
    
    
    
66. BARAKAT LA, Elsergany AR, Ghattas MH, Mahsoub N, et al
    Relationship between interferon-induced transmembrane protein 3 and matrix metalloproteinase-9 gene polymorphisms in patients with hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102110.
    PubMed     Abstract available
    
    
    
67. LAZO-DE-LA-VEGA-MONROY ML, Preciado-Puga MD, Ruiz-Noa Y, Salum-Zertuche M, et al
    Correlation of the pediatric metabolic index with NAFLD or MAFLD diagnosis, and serum adipokine levels in children.
    Clin Res Hepatol Gastroenterol. 2023;47:102137.
    PubMed     Abstract available
    
    
    
68. MEURER A, Antoni C, Ebert MP, Trimborn A, et al
    Spontaneous bacterial peritonitis caused by Listeria monocytogenes: A rare infection with very high leukocyte counts in ascitic fluid-case report and review of the literature.
    Clin Res Hepatol Gastroenterol. 2023;47:102130.
    PubMed     Abstract available
    
    
    April 2023
69. SASAKI M, Sato Y, Nakanuma Y
    An involvement of Hippo-yes-associated protein pathway in biliary epithelial senescence in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2023;47:102106.
    PubMed     Abstract available
    
    
    
70. DUAN Y, Hou X, Guo J, Li H, et al
    D-dimer for assessment of treatment response, and survival to drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102096.
    PubMed     Abstract available
    
    
    March 2023
71. HARING MPD, de Haas RJ, van Vilsteren FGI, Klaase JM, et al
    Variation in the management of benign liver tumors: A European survey and case vignette study.
    Clin Res Hepatol Gastroenterol. 2023;47:102094.
    PubMed     Abstract available
    
    
    
72. CAO L, Qu N, Wang X, Chen L, et al
    The function of long non-coding RNA in non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102095.
    PubMed     Abstract available
    
    
    February 2023
73. IANNONE G, Pompili E, Renzulli M, Caraceni P, et al
    A case of peri-stomal ectopic variceal bleeding in a patient with decompensated cirrhosis treated with TIPS placement.
    Clin Res Hepatol Gastroenterol. 2023 Feb 24:102098.
    PubMed     Abstract available
    
    
    
74. JENVRIN A, Galletto-Pregliasco A, Audureau E, Pujals A, et al
    Intentional R1 resection of liver metastases: A new treatment paradigm for patients with advanced colorectal cancer based on a propensity score-matched case-control analysis.
    Clin Res Hepatol Gastroenterol. 2023 Feb 18:102097.
    PubMed     Abstract available
    
    
    
75. JI PT, Wang XY
    Clinical application study on miR-98-5p as a prognostic biomarker in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102077.
    PubMed     Abstract available
    
    
    
76. ZHANG L, Zhang X, Li Q, Makamure J, et al
    Transarterial chemoembolization failure in patients with hepatocellular carcinoma: Incidence, manifestation and risk factors.
    Clin Res Hepatol Gastroenterol. 2023;47:102071.
    PubMed     Abstract available
    
    
    
77. XIONG W, Qian Z, Mao X, Li J, et al
    T lymphocyte-mediated pyroptosis: A new regulatory mechanism in non-viral liver disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102070.
    PubMed     Abstract available
    
    
    
78. MURALI AR, Prakash S, Sanchez AJ
    Alpha-1-Antitrypsin Pi*MZ variant increases risk of developing hepatic events in nonalcoholic fatty liver disease patients().
    Clin Res Hepatol Gastroenterol. 2023;47:102066.
    PubMed     Abstract available
    
    
    
79. ALLAIRE M, Manfredi S, Lerosey L, Ganne-Carrie N, et al
    Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey.
    Clin Res Hepatol Gastroenterol. 2023;47:102059.
    PubMed     Abstract available
    
    
    
80. ASGARZDEH A, Habibzadeh S, Asghariazar V, Safarzadeh E, et al
    Drug-induced hepatitis (DIH) after SARS-CoV-2 vaccination.
    Clin Res Hepatol Gastroenterol. 2023;47:102028.
    PubMed    
    
    
    January 2023
81. BECCHETTI C, Lange NF, Delgado MG, Bronnimann MP, et al
    2D shear wave elastography of the rectus femoris muscle in patients with cirrhosis: feasibility and clinical findings. A pilot study.
    Clin Res Hepatol Gastroenterol. 2023 Jan 16:102080.
    PubMed     Abstract available
    
    
    
82. LIU L, Sun S, Li X
    LncRNA ZFAS1 ameliorates injury led by non-alcoholic fatty liver disease via suppressing lipid peroxidation and inflammation.
    Clin Res Hepatol Gastroenterol. 2023;47:102067.
    PubMed     Abstract available
    
    
    
83. TIAN H, Zhang K, Hui Z, Ren F, et al
    Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019.
    Clin Res Hepatol Gastroenterol. 2023;47:102068.
    PubMed     Abstract available
    
    
    
84. DU F, Zhang L, Zhang Y, Fan H, et al
    Efficacy and safety of no-touch radiofrequency ablation for small hepatocellular carcinoma-a systematic review and single-arm meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102069.
    PubMed     Abstract available
    
    
    
85. ZHANG P, Dong X, Zhang W, Wang S, et al
    Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102063.
    PubMed     Abstract available
    
    
    
86. HU L, Zheng Y, Lin J, Shi X, et al
    Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102061.
    PubMed     Abstract available
    
    
    
87. WANG M, Sun L, Han X, Ren J, et al
    The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
    Clin Res Hepatol Gastroenterol. 2023;47:102060.
    PubMed     Abstract available
    
    
    
88. YANG Y, Wang Y, Wang C, Wu S, et al
    Macrophages and derived-TNF-alpha promote lipopolysaccharide-induced upregulation of endogenous beta-glucuronidase in the epithelial cells of the bile duct: A possible facilitator of hepatolithiasis formation.
    Clin Res Hepatol Gastroenterol. 2023;47:102062.
    PubMed     Abstract available
    
    
    
89. OKADA S, Kashima K, Okada K, Okada J, et al
    Aging affects FIB-4 index in the general population without pre-existing diseases: Analysis of a cohort of healthy individuals who underwent annual health checkups for 10 consecutive years.
    Clin Res Hepatol Gastroenterol. 2023;47:102058.
    PubMed    
    
    
    
90. ZOU CY, Sun Y, Liang J
    Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis(,).
    Clin Res Hepatol Gastroenterol. 2023;47:102053.
    PubMed     Abstract available
    
    
    
91. YANG XS, Li XH, Yan CY, Wei JP, et al
    Different 18F-FDG imaging: A rare case of liver multiple carcinomas.
    Clin Res Hepatol Gastroenterol. 2023;47:102050.
    PubMed     Abstract available
    
    
    December 2022
92. LUO QQ, Wang T, Zhang KH
    New indexes derived from routine blood tests and their clinical application in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:102043.
    PubMed     Abstract available
    
    
    
93. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Drug induced hepatitis and SARS-CoV-2 vaccination: Correspondence.
    Clin Res Hepatol Gastroenterol. 2022;46:102034.
    PubMed    
    
    
    
94. SU Y, Xie R, Xu Q
    LncRNA THAP9-AS1 highly expressed in tissues of hepatocellular carcinoma and accelerates tumor cell proliferation.
    Clin Res Hepatol Gastroenterol. 2022;46:102025.
    PubMed     Abstract available
    
    
    
95. MOHAMED MMG, Osman A, El-Halawany H
    Plasma exchange for patients with acute or acute on chronic liver failure; meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2022;46:102014.
    PubMed    
    
    
    
96. ZHANG X, Song W, Zhang M, Song Y, et al
    Identification of differentially expressed miRNAs and key genes involved in the progression of alcoholic fatty liver disease using rat models.
    Clin Res Hepatol Gastroenterol. 2022;46:102012.
    PubMed     Abstract available
    
    
    
97. ZHAO E, Chen S
    Association of serum C-peptide with all-cause and cardiovascular disease mortality in ultrasound-defined nonalcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:102002.
    PubMed     Abstract available
    
    
    
98. DANIEL-ROBIN T, Benichou B, Leboucher C, Blein C, et al
    Epidemiology, treatment and burden of Wilson disease in France: A 10-year analysis of the national health insurance database.
    Clin Res Hepatol Gastroenterol. 2022;46:101992.
    PubMed     Abstract available
    
    
    
99. LIU T, Yuan Z, Wang H, Wang J, et al
    Peroxisome-related genes in hepatocellular carcinoma correlated with tumor metabolism and overall survival.
    Clin Res Hepatol Gastroenterol. 2022;46:101835.
    PubMed     Abstract available
    
    
    November 2022
100. LI N, Yang P, Fang J
     Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2022;46:102022.
     PubMed     Abstract available
     
     
     
101. WASUWANICH P, Choudry H, So JM, Lowry S, et al
     Vanishing bile duct syndrome after drug-induced liver injury.
     Clin Res Hepatol Gastroenterol. 2022;46:102015.
     PubMed     Abstract available
     
     
     
102. SHARMA D, Mandal P
     NAFLD: genetics and its clinical implications.
     Clin Res Hepatol Gastroenterol. 2022;46:102003.
     PubMed     Abstract available
     
     
     
103. WU L, Yang J, Ke RS, Liu Y, et al
     Impact of lncRNA SOX9-AS1 overexpression on the prognosis and progression of intrahepatic cholangiocarcinoma.
     Clin Res Hepatol Gastroenterol. 2022;46:101999.
     PubMed     Abstract available
     
     
     
104. ISSA Z, Gohy S, Zech F, Baldin P, et al
     Prevalence and characteristics of cystic fibrosis liver disease: a study highlighting the lack of histological diagnosis.
     Clin Res Hepatol Gastroenterol. 2022;46:101977.
     PubMed     Abstract available
     
     
     
105. FANG Z, Yang H, Mao Y
     Letter to the editor: Liver transarterial chemoembolization plus sunitinib for unresectable hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2022;46:101984.
     PubMed    
     
     
     
106. GUILLAUD O, Woimant F, Couchonnal E, Dumortier J, et al
     Maintenance therapy simplification using a single daily dose: A preliminary real-life feasibility study in patients with Wilson disease.
     Clin Res Hepatol Gastroenterol. 2022;46:101978.
     PubMed     Abstract available
     
     
     October 2022
107. WANG J, Lun W, Shi W
     Effects of elevated bile acid levels on fetal myocardium in intrahepatic cholestasis of pregnancy, a retrospective study from a neonatal perspective.
     Clin Res Hepatol Gastroenterol. 2022;46:102013.
     PubMed     Abstract available
     
     
     
108. QIU JJ, Wei GF, Du JL, Guo J, et al
     Advances in the application of different anesthetic methods and drugs in interventional therapy for hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2022;46:101982.
     PubMed     Abstract available
     
     
     
109. STEENSIG K, Pareek M, Krarup AL, Sogaard P, et al
     Thromboembolism and bleeding in patients with atrial fibrillation and liver disease - A nationwide register-based cohort study: Thromboembolism and bleeding in liver disease.
     Clin Res Hepatol Gastroenterol. 2022;46:101952.
     PubMed     Abstract available
     
     
     
110. DING Y, Jiang L, Wang Q, Zhao W, et al
     The prevalence of nonalcoholic fatty liver disease in Chinese adults screened by vibration controlled transient elastography and its diagnostic discrepancy compared with ultrasound.
     Clin Res Hepatol Gastroenterol. 2022;46:101951.
     PubMed     Abstract available
     
     
     
111. BOGOVIC N, Doenecke A, Hart C, Lurken L, et al
     Covid19 vaccination-associated portal vein thrombosis-An interdisciplinary clinical challenge.
     Clin Res Hepatol Gastroenterol. 2022;46:101932.
     PubMed     Abstract available
     
     
     
112. JAIN A, Sobotka LA, Wellner MR
     A rare mimicker of hepatocellular carcinoma: Syphilis.
     Clin Res Hepatol Gastroenterol. 2022;46:101919.
     PubMed    
     
     
     
113. BRAN DM, Fuks D, Lansier A, Gallois C, et al
     Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin.
     Clin Res Hepatol Gastroenterol. 2022;46:101920.
     PubMed    
     
     
     
114. THABUT D, Weil D, Bouzbib C, Rudler M, et al
     Non-invasive diagnosis and follow-up of portal hypertension.
     Clin Res Hepatol Gastroenterol. 2022;46:101767.
     PubMed     Abstract available
     
     
     August 2022
115. SOURIANARAYANANE A, McCullough AJ
     Accuracy of steatosis and fibrosis NAFLD scores in relation to vibration controlled transient elastography: An NHANES analysis.
     Clin Res Hepatol Gastroenterol. 2022;46:101997.
     PubMed     Abstract available
     
     
     
116. SHI Q, Wang F, Du N, Zhou Y, et al
     Microwave ablation combined with lipiodol-microsphere mixed or conventional transarterial chemoembolization for the treatment of colorectal liver metastases: A retrospective study.
     Clin Res Hepatol Gastroenterol. 2022;46:101986.
     PubMed     Abstract available
     
     
     
117. SALTEL F, Blanc JF
     Hepatocellular carcinoma treatments: A new hope, but a headache for clinicians and researchers.
     Clin Res Hepatol Gastroenterol. 2022;46:101927.
     PubMed    
     
     
     
118. CHEN SQ, He K, Xiao XL
     Multifocal nodular fatty infiltration of the liver: A donut-shaped appearance.
     Clin Res Hepatol Gastroenterol. 2022;46:101985.
     PubMed    
     
     
     
119. DIAS E, Cardoso H, Pacheco J, Lopes J, et al
     Ciliated hepatic foregut cyst: An uncommon cystic liver lesion.
     Clin Res Hepatol Gastroenterol. 2022;46:101949.
     PubMed    
     
     
     
120. ZAFAR Y, Rashid AM, Siddiqi AK, Ellahi A, et al
     Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
     Clin Res Hepatol Gastroenterol. 2022;46:101970.
     PubMed     Abstract available
     
     
     
121. CALES P, Ravaioli F, Berger A, Farcau O, et al
     Comparison of screening strategies with two new tests to score and diagnose varices needing treatment.
     Clin Res Hepatol Gastroenterol. 2022;46:101925.
     PubMed     Abstract available
     
     
     June 2022
122. NAYAGAM JS, Mandour MO, Taylor A, Heneghan MA, et al
     Clinical course of inflammatory bowel disease and impact on liver disease outcomes in patients with autoimmune sclerosing cholangitis.
     Clin Res Hepatol Gastroenterol. 2022 Jun 18:101980.
     PubMed     Abstract available
     
     
     
123. ADDEO P, Foguenne M, Michard B, Artzner T, et al
     Emergency reversal of a Roux-en-Y Gastric bypass to rescue liver graft from recurrent steatohepatitis.
     Clin Res Hepatol Gastroenterol. 2022;46:101971.
     PubMed    
     
     
     
124. CHOU TP, Hu JT, Hung CS, Chen HY, et al
     Sorafenib-induced liver failure in a hepatocellular carcinoma patient: Letter to the editor.
     Clin Res Hepatol Gastroenterol. 2022;46:101931.
     PubMed    
     
     
     
125. BARBIER L, Cauchy F
     What assessment of the liver before resection for hepatocellular carcinoma?
     Clin Res Hepatol Gastroenterol. 2022;46:101916.
     PubMed    
     
     
     
126. LIU X, Luo J, Zhang L, Yang F, et al
     SIB-IMRT combined with apatinib for unresectable hepatocellular carcinoma in patients with poor response to transarterial chemoembolization.
     Clin Res Hepatol Gastroenterol. 2022;46:101897.
     PubMed     Abstract available
     
     
     
127. WANG H, Liu D, Wang C, Yu S, et al
     Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study.
     Clin Res Hepatol Gastroenterol. 2022;46:101869.
     PubMed     Abstract available
     
     
     May 2022
128. MOREIRA-SILVA H, Amorim J, Santos-Silva E
     Incidental Liver Lesions in children: A practical and evidence-based approach.
     Clin Res Hepatol Gastroenterol. 2022;46:101904.
     PubMed     Abstract available
     
     
     
129. ELGENIDY A, Afifi AM, Awad AK, Jalal PK, et al
     Utility of serum angiopoietin-2 as diagnostic marker of hepatocellular carcinoma: A systematic review and diagnostic test accuracy meta-analysis.
     Clin Res Hepatol Gastroenterol. 2022;46:101909.
     PubMed    
     
     
     
130. SHI Q, Liu J, Li T, Zhou C, et al
     Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
     Clin Res Hepatol Gastroenterol. 2022;46:101893.
     PubMed     Abstract available
     
     
     
131. BOULOUTA A, Aggeletopoulou I, Kanaloupitis S, Tsounis EP, et al
     The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience.
     Clin Res Hepatol Gastroenterol. 2022;46:101896.
     PubMed     Abstract available
     
     
     
132. TRIPON S, Bilbault P, Fabacher T, Lefebvre N, et al
     Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with COVID-19.
     Clin Res Hepatol Gastroenterol. 2022;46:101894.
     PubMed     Abstract available
     
     
     
133. YOU Y, Hu S
     Aberrant expression of the esophageal carcinoma related gene 4 as a prognostic signature for hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2022;46:101891.
     PubMed     Abstract available
     
     
     
134. ZHAO Y, Zhang C, Zhang Y, Bo C, et al
     Effects of image-guided adaptive radiotherapy combined with hepatic artery chemoembolization in primary liver cancer patients.
     Clin Res Hepatol Gastroenterol. 2022;46:101889.
     PubMed     Abstract available
     
     
     April 2022
135. BOILLOT O, Chopinet S, Gregoire E, Milot L, et al
     Partial splenectomy in children undergoing liver transplantation or venous shunt for severe hypersplenism: a case control comparative study.
     Clin Res Hepatol Gastroenterol. 2022 Apr 21:101929.
     PubMed     Abstract available
     
     
     
136. WARASNHE K, Ozcay F, Aydin HI, Ozgun G, et al
     A Novel Mutation in TRMT5 Associated with Idiopathic Non-Cirrhotic Portal Hypertension and Hepatopulmonary Syndrome: Case Report of Two Siblings.
     Clin Res Hepatol Gastroenterol. 2022 Apr 20:101928.
     PubMed     Abstract available
     
     
     
137. SUN L, Deng C, Gu Y, He Y, et al
     Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
     Clin Res Hepatol Gastroenterol. 2022;46:101876.
     PubMed     Abstract available
     
     
     
138. ZHANG X, Jiang M, Zhang X, Zhang J, et al
     An extracellular matrix-based signature associated with immune microenvironment predicts the prognosis of patients with hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2022;46:101877.
     PubMed     Abstract available
     
     
     
139. JAIN A, Kirkpatrick RB, Sobotka LA
     Severe pruritis during pregnancy: More than just intrahepatic cholestasis of pregnancy?
     Clin Res Hepatol Gastroenterol. 2022;46:101875.
     PubMed    
     
     
     
140. LI L, Xin Y, Zhang X, Chen Y, et al
     The effectiveness of radiofrequency ablation for patients with BCLC B1 stage hepatocellular carcinoma downgraded by transarterial chemoembolization.
     Clin Res Hepatol Gastroenterol. 2022;46:101878.
     PubMed     Abstract available
     
     
     
141. HOORNAERT E, Yombi JC, Coubeau L, Baldin P, et al
     Liver hypodense infectious lesions: Is it only bacteria, parasites or fungi?
     Clin Res Hepatol Gastroenterol. 2022;46:101872.
     PubMed    
     
     
     
142. WASUWANICH P, So JM, Scheimann AO, Spahic H, et al
     Hepatic and non-hepatic hydrothorax in pediatric ascites.
     Clin Res Hepatol Gastroenterol. 2022;46:101868.
     PubMed     Abstract available
     
     
     
143. ARTRU F, Moschouri E, Denys A
     Direct intrahepatic portocaval shunt (DIPS) or transjugular transcaval intrahepatic portosystemic shunt (TTIPS) to treat complications of portal hypertension: Indications, technique, and outcomes beyond Budd-Chiari syndrome.
     Clin Res Hepatol Gastroenterol. 2022;46:101858.
     PubMed     Abstract available
     
     
     
144. WANG H, He X, Fang D, Wang X, et al
     Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
     Clin Res Hepatol Gastroenterol. 2022;46:101853.
     PubMed     Abstract available
     
     
     
145. ZHANG S, Zhao Y, He L, Bo C, et al
     Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2022;46:101851.
     PubMed     Abstract available
     
     
     
146. CANIVET CM, Smati S, Lannes A, Brisseau J, et al
     Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners.
     Clin Res Hepatol Gastroenterol. 2022;46:101848.
     PubMed     Abstract available
     
     
     
147. ZHU X, Lin X, Zhang P, Liu Y, et al
     Upregulated NLRP3 inflammasome activation is attenuated by anthocyanins in patients with nonalcoholic fatty liver disease: A case-control and an intervention study.
     Clin Res Hepatol Gastroenterol. 2022;46:101843.
     PubMed     Abstract available
     
     
     
148. ATHYROS VG, Katsiki N, Mikhailidis DP
     Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis.
     Clin Res Hepatol Gastroenterol. 2022;46:101842.
     PubMed    
     
     
     
149. ZHANG C, Zhang B, Chen A, Yin Q, et al
     Trans-anethole attenuates diet-induced nonalcoholic steatohepatitis through suppressing TGF-beta-mediated fibrosis.
     Clin Res Hepatol Gastroenterol. 2022;46:101833.
     PubMed     Abstract available
     
     
     
150. SHAHID A, Cheema HA
     Can statins finally provide the breakthrough in the treatment of non-alcoholic fatty liver disease?
     Clin Res Hepatol Gastroenterol. 2022;46:101826.
     PubMed    
     
     
     
151. LYU T, Yao H, Wang J, Song L, et al
     Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus.
     Clin Res Hepatol Gastroenterol. 2022;46:101819.
     PubMed     Abstract available
     
     
     
152. FATIMA K, Moeed A, Waqar E, Atif AR, et al
     Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
     Clin Res Hepatol Gastroenterol. 2022;46:101816.
     PubMed     Abstract available
     
     
     
153. LONCAR Y, Tartrat N, Lastennet D, Lemoine L, et al
     Pulmonary infection after hepatic resection: Associated factors and impact on outcomes.
     Clin Res Hepatol Gastroenterol. 2022;46:101733.
     PubMed     Abstract available
     
     
     March 2022
154. CORDEIRO A, Ribamar A, Ramalho A
     Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19.
     Clin Res Hepatol Gastroenterol. 2022;46:101807.
     PubMed     Abstract available
     
     
     
155. JU S, Wang W, Chen P, Li F, et al
     Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C.
     Clin Res Hepatol Gastroenterol. 2022;46:101859.
     PubMed     Abstract available
     
     
     
156. DUMORTIER J, Simon M, Bouhour F
     Fatal myositis and myasthenia induced by atezolizumab for the treatment of hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2022;46:101854.
     PubMed    
     
     
     
157. DANA J, Girard M, Franchi-Abella S, Berteloot L, et al
     Comparison of Transient Elastography, ShearWave Elastography, Magnetic Resonance Elastography and FibroTest as routine diagnostic markers for assessing liver fibrosis in children with Cystic Fibrosis.
     Clin Res Hepatol Gastroenterol. 2022;46:101855.
     PubMed     Abstract available
     
     
     
158. LI J, Huang WF, Zhang JY
     A rare case of duodenal neuroendocrine tumor with hepatic metastasis.
     Clin Res Hepatol Gastroenterol. 2022;46:101850.
     PubMed    
     
     
     
159. TANG J, Chen C, Zhou M, Wang J, et al
     NLR contributed to the diagnosis and detection of nonalcoholic fatty liver disease: A meta - analysis.
     Clin Res Hepatol Gastroenterol. 2022;46:101847.
     PubMed    
     
     
     
160. VALTIS YK, Barlowe T, Young JH, Lichtman AH, et al
     A woman presenting with an unusual cause of fulminant liver failure and sepsis.
     Clin Res Hepatol Gastroenterol. 2022;46:101836.
     PubMed     Abstract available
     
     
     
161. WU D, Zhang R, Zhan L
     Transglutaminase 3 expression in hepatocellular carcinoma patients: Correlation with tumor features and survival profile.
     Clin Res Hepatol Gastroenterol. 2022;46:101812.
     PubMed     Abstract available
     
     
     
162. TANG J, Huang Z, Xu J, Lv Q, et al
     Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
     Clin Res Hepatol Gastroenterol. 2022;46:101814.
     PubMed     Abstract available
     
     
     
163. SCHAEFER A, Journaux M, Mourabit HE, Mouri S, et al
     A systemic mechanism of increased transendothelial migration of leukocytes through the blood-brain barrier in hepatic encephalopathy.
     Clin Res Hepatol Gastroenterol. 2022;46:101801.
     PubMed     Abstract available
     
     
     
164. BATOOL SS, Dauer M, Weber SN, Liebe R, et al
     Intrahepatic cholestasis of pregnancy in conjunction with a frameshift deletion in FGFR4.
     Clin Res Hepatol Gastroenterol. 2022;46:101800.
     PubMed     Abstract available
     
     
     
165. CAI Y, Wu D, Zhan L
     CCT6A expression in hepatocellular carcinoma and its correlation with clinical characteristics, liver function indexes, tumor markers and prognosis.
     Clin Res Hepatol Gastroenterol. 2022;46:101796.
     PubMed     Abstract available
     
     
     
166. PAPAEFTHYMIOU A, Koffas A, Laskaratos FM, Epstein O, et al
     Upper gastrointestinal video capsule endoscopy: The state of the art.
     Clin Res Hepatol Gastroenterol. 2022;46:101798.
     PubMed     Abstract available
     
     
     February 2022
167. THOMAS LS, Geoffroy V, Patrick C, Rodolphe A, et al
     Infectious complications of portal biliopathy leading to liver transplantation.
     Clin Res Hepatol Gastroenterol. 2022 Feb 10:101879.
     PubMed    
     
     
     
168. KAPS L, Hildebrand K, Nagel M, Michel M, et al
     Validation of EncephalApp_Stroop as screening tool for the detection of minimal hepatic encephalopathy in German patients with liver cirrhosis.
     Clin Res Hepatol Gastroenterol. 2022 Feb 3:101873.
     PubMed     Abstract available
     
     
     
169. DU M, Yang S, Liu M, Liu J, et al
     COVID-19 and liver dysfunction: Epidemiology, association and potential mechanisms.
     Clin Res Hepatol Gastroenterol. 2022;46:101793.
     PubMed     Abstract available
     
     
     
170. MACEDO MB, Giardini HAM, Pereira RMR
     A retracted diagnosis-when liver capsule retraction is not what it seems.
     Clin Res Hepatol Gastroenterol. 2022;46:101823.
     PubMed    
     
     
     
171. VITELLIUS C, Paisant A, Lannes A, Chaigneau J, et al
     Liver fibrosis staging by computed tomography: Prospective randomized multicentric evaluation of image analyses.
     Clin Res Hepatol Gastroenterol. 2022;46:101797.
     PubMed     Abstract available
     
     
     
172. HE S, Chen W, Yang Y, Tang X, et al
     Adult diffuse hepatic hemangiomatosis: A case report and review of the literature.
     Clin Res Hepatol Gastroenterol. 2022;46:101789.
     PubMed     Abstract available
     
     
     
173. WANG L, Peng Y, Qian Y, Liu Z, et al
     Transjugular extrahepatic portosystemic shunt (TEPS) creation in patients with complete occlusion of portal vein: Primary experience in a single medical center.
     Clin Res Hepatol Gastroenterol. 2022;46:101786.
     PubMed    
     
     
     
174. CAMPION B, Larrey E, Wagner M, Rudler M, et al
     Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage a trois" !
     Clin Res Hepatol Gastroenterol. 2022;46:101785.
     PubMed    
     
     
     
175. HUANG L, Liu J, Bie C, Liu H, et al
     Advances in cell death - related signaling pathways in acute-on-chronic liver failure.
     Clin Res Hepatol Gastroenterol. 2022;46:101783.
     PubMed     Abstract available
     
     
     
176. LI Q, Xu H, Sui C, Zhang H, et al
     Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.
     Clin Res Hepatol Gastroenterol. 2022;46:101781.
     PubMed     Abstract available
     
     
     January 2022
177. XIN H, Zhang C, Ding Z, Zhang M, et al
     TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports.
     Clin Res Hepatol Gastroenterol. 2022;46:101777.
     PubMed    
     
     
     
178. NAULT JC, Blanc JF, Moga L, Calderaro J, et al
     Non-invasive diagnosis and follow-up of benign liver tumours.
     Clin Res Hepatol Gastroenterol. 2022;46:101765.
     PubMed     Abstract available
     
     
     
179. DE LEDINGHEN V
     Non-invasive diagnosis and follow-up of chronic liver disease.
     Clin Res Hepatol Gastroenterol. 2022;46:101763.
     PubMed    
     
     
     
180. NAHON P, Aube C, Moga L, Chalaye J, et al
     Non-invasive diagnosis and follow-up of primary malignant liver tumours.
     Clin Res Hepatol Gastroenterol. 2022;46:101766.
     PubMed     Abstract available
     
     
     
181. CORPECHOT C, Heurgue A, Tanne F, Potier P, et al
     Non-invasive diagnosis and follow-up of primary biliary cholangitis.
     Clin Res Hepatol Gastroenterol. 2022;46:101770.
     PubMed     Abstract available
     
     
     
182. BOURSIER J, Guillaume M, Bouzbib C, Lannes A, et al
     Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease.
     Clin Res Hepatol Gastroenterol. 2022;46:101769.
     PubMed     Abstract available
     
     
     
183. RAUTOU PE, Elkrief L, Decraecker M, Ollivier-Hourmand I, et al
     Non-invasive diagnosis and follow-up of vascular liver diseases.
     Clin Res Hepatol Gastroenterol. 2022;46:101764.
     PubMed     Abstract available
     
     
     
184. SOBESKY R, Guillaud O, Bouzbib C, Sogni P, et al
     Non-invasive diagnosis and follow-up of rare genetic liver diseases.
     Clin Res Hepatol Gastroenterol. 2022;46:101768.
     PubMed     Abstract available
     
     
     
185. BOURSIER J, Decraecker M, Bourliere M, Bureau C, et al
     Quality criteria for the measurement of liver stiffness.
     Clin Res Hepatol Gastroenterol. 2022;46:101761.
     PubMed     Abstract available
     
     
     
186. CHEN BR, Pan CQ
     Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease.
     Clin Res Hepatol Gastroenterol. 2022;46:101755.
     PubMed     Abstract available
     
     
     
187. STEMPAK-DROISSART T, Rousset-Jablonski C, Spritzer PM, Lalhou N, et al
     Impact of vascular liver disease on the menstrual cycle and metabolic status in premenopausal women.
     Clin Res Hepatol Gastroenterol. 2022;46:101756.
     PubMed     Abstract available
     
     
     
188. HOUNTONDJI L, Debourdeau A, Meunier L
     Acute liver failure secondary to Langerhans cell histiocytosis.
     Clin Res Hepatol Gastroenterol. 2022;46:101744.
     PubMed    
     
     
     
189. ZIMMER V, Emrich K
     Nodular gastric antral vascular ectasia: Distinct portal hypertensive hyperplastic polyp lesions.
     Clin Res Hepatol Gastroenterol. 2022;46:101745.
     PubMed    
     
     
     
190. DU J, Zhang J, Chen X, Zhang S, et al
     Neutrophil extracellular traps induced by pro-inflammatory cytokines enhance procoagulant activity in NASH patients.
     Clin Res Hepatol Gastroenterol. 2022;46:101697.
     PubMed     Abstract available
     
     
     December 2021
191. BORIE F, Dubray V, Tretarre B
     Impact of recommendations and new therapies on the prognosis of colon cancer with synchronous liver metastasis.
     Clin Res Hepatol Gastroenterol. 2021 Dec 25:101856.
     PubMed     Abstract available
     
     
     November 2021
192. SOBOTKA LA, Mumtaz K, Hinton A, Conteh LF, et al
     The Time to Advocate for Influenza Vaccines in Patients with Cirrhosis is Now.
     Clin Res Hepatol Gastroenterol. 2021 Nov 20:101838.
     PubMed     Abstract available
     
     
     
193. MOREIRA JLS, Barbosa SMB, Goncalves Junior J
     Pathophysiology and molecular mechanisms of liver injury in severe forms of COVID-19: An integrative review.
     Clin Res Hepatol Gastroenterol. 2021;45:101752.
     PubMed     Abstract available
     
     
     
194. THOEN RU, Longo L, Neto SC, Alvares-da-Silva MR, et al
     Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease.
     Clin Res Hepatol Gastroenterol. 2021;45:101638.
     PubMed     Abstract available
     
     
     
195. RUTHER DF, Sebode M, Lohse AW, Wernicke S, et al
     Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER.
     Clin Res Hepatol Gastroenterol. 2021;45:101760.
     PubMed     Abstract available
     
     
     
196. TUTUNCHI H, Naeini F, Ebrahimi-Mameghani M, Najafipour F, et al
     Metabolically healthy and unhealthy obesity and the progression of liver fibrosis: A cross-sectional study.
     Clin Res Hepatol Gastroenterol. 2021;45:101754.
     PubMed     Abstract available
     
     
     
197. ZHAO J, Wang Y, Su H, Su L, et al
     Non-coding RNAs as biomarkers for hepatocellular carcinoma-A systematic review.
     Clin Res Hepatol Gastroenterol. 2021;45:101736.
     PubMed     Abstract available
     
     
     
198. BLAISE L, Pereira H, Vilgrain V, Sutter O, et al
     Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion.
     Clin Res Hepatol Gastroenterol. 2021;45:101731.
     PubMed     Abstract available
     
     
     
199. WONG YJ, Kew GS, Tan PS, Chen Z, et al
     Novel albumin, bilirubin and platelet criteria for the exclusion of high-risk varices in compensated advanced chronic liver disease: A validation study.
     Clin Res Hepatol Gastroenterol. 2021;45:101598.
     PubMed     Abstract available
     
     
     
200. MOTAMED N, Nikkhah M, Karbalaie Niya MH, Khoonsari M, et al
     The Ability of the Framingham Steatosis Index (FSI) to Predict Non-alcoholic Fatty Liver Disease (NAFLD): A Cohort Study.
     Clin Res Hepatol Gastroenterol. 2021;45:101567.
     PubMed     Abstract available
     
     
     
201. BOUZBIB C, Cluzel P, Sultanik P, Bernard-Chabert B, et al
     Prognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era.
     Clin Res Hepatol Gastroenterol. 2021;45:101593.
     PubMed     Abstract available
     
     
     
202. HOU H, Chen D, Liu J, Feng L, et al
     Zinc monotherapy for young patients with oligosymptomatic Wilson disease: A single center, retrospective study.
     Clin Res Hepatol Gastroenterol. 2021;45:101623.
     PubMed     Abstract available
     
     
     
203. GE J, Zhang X, Zhang B, Zhu L, et al
     Higher tumor protein kinase D1 correlates with increased tumor size, BCLC stage, CA199 level, AFP level and worse overall survival in hepatocellular carcinoma patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101573.
     PubMed     Abstract available
     
     
     
204. LI X, Yu Y, Liu L
     Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis.
     Clin Res Hepatol Gastroenterol. 2021;45:101545.
     PubMed     Abstract available
     
     
     
205. VEYRE F, Dumortier J, Radenne S, Valette PJ, et al
     Rare isolated spontaneous hepatic artery thrombosis in a non-transplant patient.
     Clin Res Hepatol Gastroenterol. 2021;45:101453.
     PubMed    
     
     
     
206. VANDE BERG P, Borbath I, Baldin P, Vande Berg D, et al
     Granuloma formation within perihepatic lymphadenopathy.
     Clin Res Hepatol Gastroenterol. 2021;45:101504.
     PubMed    
     
     
     
207. ABDI SAH, Shukla S, Khan J, Al Zahrani A, et al
     Hepatotoxicity is the risk factor with gemtuzumab ozogamicin treatment in acute myelogenous leukaemia patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101443.
     PubMed    
     
     
     October 2021
208. ZHANG L, Zhou Y, Zhang J
     An incidental hepatic lesion in a cirrhotic liver.
     Clin Res Hepatol Gastroenterol. 2021 Oct 28:101825.
     PubMed    
     
     
     
209. MOGA L, Robic MA, Blasco-Perrin H, Cabarrou P, et al
     Acute kidney injury in patients with cirrhosis: prospective longitudinal study in 405 patients.
     Clin Res Hepatol Gastroenterol. 2021 Oct 27:101822.
     PubMed     Abstract available
     
     
     
210. ARTZNER T, Legeai C, Antoine C, Jasseron C, et al
     Liver transplantation for critically ill cirrhotic patients: results from the French transplant registry.
     Clin Res Hepatol Gastroenterol. 2021 Oct 1:101817.
     PubMed     Abstract available
     
     
     September 2021
211. CHAIBI S, Boussier J, Hajj WE, Abitbol Y, et al
     Liver function test abnormalities are associated with a poorer prognosis in Covid-19 patients: Results of a French cohort.
     Clin Res Hepatol Gastroenterol. 2021;45:101556.
     PubMed     Abstract available
     
     
     
212. MALEZIEUX E, Meunier L, Riviere B, Larrey D, et al
     Hydrochlorothiazide-induced hepatotoxicity: A rare case of DILI.
     Clin Res Hepatol Gastroenterol. 2021;45:101599.
     PubMed     Abstract available
     
     
     
213. CHEN S, Zhao E
     Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2021;45:101587.
     PubMed     Abstract available
     
     
     
214. BAUMANN U, Sturm E, Lacaille F, Gonzales E, et al
     Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
     Clin Res Hepatol Gastroenterol. 2021;45:101751.
     PubMed     Abstract available
     
     
     
215. WAHLIN S, Andersson J
     Liver health literacy and social stigma of liver disease: A general population e-survey.
     Clin Res Hepatol Gastroenterol. 2021;45:101750.
     PubMed     Abstract available
     
     
     
216. LI X, Yao Q, Li R, Jin Y, et al
     Isoflurane induces liver injury by modulating the expression of miR-125a-5p.
     Clin Res Hepatol Gastroenterol. 2021;45:101732.
     PubMed     Abstract available
     
     
     
217. BENARD J, Lafrance MJ, Gordien E, Amaral L, et al
     Hepatitis B virus-associated hepatocellular carcinoma is still a matter of concern in the French Caribbean Island of Guadeloupe.
     Clin Res Hepatol Gastroenterol. 2021;45:101706.
     PubMed    
     
     
     
218. YANG M, Wei S, Zhao H, Zhou D, et al
     The role of miRNA125b in the progression of hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2021;45:101712.
     PubMed     Abstract available
     
     
     
219. LUO L, He X, Li K, Long Y, et al
     Thermal ablation of medium-sized hepatocellular carcinomas using intraoperative ultrasound fusion imaging: A propensity score-matched analysis.
     Clin Res Hepatol Gastroenterol. 2021;45:101581.
     PubMed     Abstract available
     
     
     
220. YANG D, Wu H, Nong W, Zheng M, et al
     A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2021;45:101509.
     PubMed     Abstract available
     
     
     
221. DE SOUSA MAGALHAES R, Xavier S, Magalhaes J, Rosa B, et al
     Transient elastography through controlled attenuated parameter assisting the stratification of cardiovascular disease risk in NAFLD patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101580.
     PubMed     Abstract available
     
     
     
222. BOEKEN T, Gallois C, Douard R, Meatchi T, et al
     Bridge to surgery after irinotecan-based liver chemoembolization for metastatic gastric adenocarcinoma: Letter to the editor.
     Clin Res Hepatol Gastroenterol. 2021;45:101557.
     PubMed    
     
     
     August 2021
223. LARREY E, Cluzel P, Rudler M, Goumard C, et al
     (TIPS for patients with early HCC: a bridge to liver transplantation).
     Clin Res Hepatol Gastroenterol. 2021 Aug 13:101790.
     PubMed     Abstract available
     
     
     
224. BOUZBIB C, El Mourabit H, Wendum D, Lasnier E, et al
     ATP-binding cassette transporters expression in rats with cirrhosis and hepatic encephalopathy.
     Clin Res Hepatol Gastroenterol. 2021 Aug 9:101784.
     PubMed     Abstract available
     
     
     July 2021
225. DUMORTIER J, Besch C, Moga L, Coilly A, et al
     NON-INVASIVE DIAGNOSIS AND FOLLOW-UP IN LIVER TRANSPLANTATION.
     Clin Res Hepatol Gastroenterol. 2021 Jul 28:101774.
     PubMed     Abstract available
     
     
     
226. VILLERET F, Dumortier J, Erard-Poinsot D
     How will NAFLD change the liver transplant landscape in the 2020s?
     Clin Res Hepatol Gastroenterol. 2021 Jul 23:101759.
     PubMed     Abstract available
     
     
     
227. LANTHIER N, Starkel P, Dahlqvist G
     Muscle mass depletion in chronic liver diseases: An accelerated model of aging or a distinct entity?
     Clin Res Hepatol Gastroenterol. 2021;45:101721.
     PubMed     Abstract available
     
     
     
228. LIU W, Xu C, Meng Q, Kang P, et al
     The clinical value of kinesin superfamily protein 2A in hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2021;45:101527.
     PubMed     Abstract available
     
     
     
229. CAMPOS-MURGUIA A, Valdez-Hernandez P, Cordova-Gallardo J, Arteaga-Vazquez J, et al
     Prevalence and clinical characteristics of alpha-1 antitrypsin deficiency in liver explants in a Mexican cohort.
     Clin Res Hepatol Gastroenterol. 2021;45:101519.
     PubMed     Abstract available
     
     
     
230. KIM KM, Roh JH, Lee S, Yoon JH, et al
     Do renin-angiotensin system inhibitors reduce risk for hepatocellular carcinoma?: A nationwide nested case-control study.
     Clin Res Hepatol Gastroenterol. 2021;45:101510.
     PubMed     Abstract available
     
     
     
231. CAI L, Li H, Guo J, Zhao W, et al
     Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.
     Clin Res Hepatol Gastroenterol. 2021;45:101535.
     PubMed     Abstract available
     
     
     
232. SHI JY, Sun LY, Quan B, Xing H, et al
     A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2021;45:101534.
     PubMed     Abstract available
     
     
     
233. IM HJ, Ahn YC, Wang JH, Lee MM, et al
     Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea.
     Clin Res Hepatol Gastroenterol. 2021;45:101526.
     PubMed     Abstract available
     
     
     
234. PERRAULT F, Echelard P, Viens D, Borduas M, et al
     Contraceptive vaginal ring-induced cholestasis in a patient with a history of intrahepatic cholestasis of pregnancy.
     Clin Res Hepatol Gastroenterol. 2021;45:101475.
     PubMed     Abstract available
     
     
     
235. LIU J, Dai XL, Zhou XJ, Gu BH, et al
     Metamizole-induced acute liver failure in a boy.
     Clin Res Hepatol Gastroenterol. 2021;45:101570.
     PubMed    
     
     
     
236. MOSCHOURI E, Hocquelet A, Vermersch M, Fraga M, et al
     DIPS, a safe and effective alternative in patients with unfavorable anatomy to TIPSS: first experience in a tertiary center.
     Clin Res Hepatol Gastroenterol. 2021;45:101715.
     PubMed    
     
     
     
237. COLAK Y, Hasan B, Erkalma B, Tandon K, et al
     Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target.
     Clin Res Hepatol Gastroenterol. 2021;45:101710.
     PubMed     Abstract available
     
     
     
238. ILUZ-FREUNDLICH D, Grubert Van Iderstine M, Uhanova J, Zhang M, et al
     Low serum alkaline phosphatase levels in patients with chronic liver diseases: Possible contributions to disease pathogenesis.
     Clin Res Hepatol Gastroenterol. 2021;45:101694.
     PubMed     Abstract available
     
     
     June 2021
239. QU Y, Li T, Lin C, Liu F, et al
     Animal Naming Test for the Assessment of Minimal Hepatic Encephalopathy in Asian Cirrhotic Populations.
     Clin Res Hepatol Gastroenterol. 2021 Jun 3:101729.
     PubMed     Abstract available
     
     
     
240. RAZAQ S, Kara M, Ozcakar L
     Measure Grip Strength, Gait Speed and Quadriceps Muscle in Cirrhosis. Comment to "Frailty, sarcopenia and mortality in cirrhosis: What is the best assessment, how to interpret the data correctly and what interventions are possible?"
     Clin Res Hepatol Gastroenterol. 2021 Jun 1:101727.
     PubMed    
     
     
     May 2021
241. VUJAKLIJA BRAJKOVIC A, Zlopasa O, Gubarev Vrdoljak N, Goran T, et al
     Acute liver and cardiac failure in multisystem inflammatory syndrome in adults after COVID-19.
     Clin Res Hepatol Gastroenterol. 2021;45:101678.
     PubMed    
     
     
     
242. SERRA F, Bonaduce I, De Ruvo N, Cautero N, et al
     Covid-19 and hepatic injury: A systematic review.
     Clin Res Hepatol Gastroenterol. 2021;45:101605.
     PubMed    
     
     
     
243. SHIHA G, Soliman R, Mikhail N, Zaky S, et al
     HCC developed in CHC patients who achieved SVR following DAAs tend to display less aggressive pattern.
     Clin Res Hepatol Gastroenterol. 2021;45:101608.
     PubMed    
     
     
     
244. WORLAND T, O'Neill P, Rusli F
     Resolution of metastatic hepatocellular carcinoma with sour cherry intake.
     Clin Res Hepatol Gastroenterol. 2021;45:101663.
     PubMed    
     
     
     
245. DEVICTOR J, Leclercq A, Hazo JB, Burnet E, et al
     Nurse coordinator roles in the management of patients with hepatocellular carcinoma: A French national survey.
     Clin Res Hepatol Gastroenterol. 2021;45:101650.
     PubMed     Abstract available
     
     
     
246. MU X, Tong J, Xu X, Chen J, et al
     World Gastroenterology Organisation classification and a new type-based prognostic model for hepatitis B virus-related acute-on-chronic liver failure.
     Clin Res Hepatol Gastroenterol. 2021;45:101548.
     PubMed     Abstract available
     
     
     
247. ARAZ M, Kilinc F, Kerimoglu U, Keskin M, et al
     Irinotecan-induced NASH and liver failure.
     Clin Res Hepatol Gastroenterol. 2021;45:101606.
     PubMed    
     
     
     
248. KALOGIROU MS, Patoulias D, Haidich AB, Akriviadis E, et al
     Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
     Clin Res Hepatol Gastroenterol. 2021;45:101568.
     PubMed     Abstract available
     
     
     
249. LIN M, Zeng H, Deng G, Lei J, et al
     Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis.
     Clin Res Hepatol Gastroenterol. 2021;45:101530.
     PubMed     Abstract available
     
     
     
250. KARNSAKUL W, Wasuwanich P, Ingviya T, Laengvejkal P, et al
     Clinical usage of serum albumin to ascitic fluid albumin gradient and ascitic fluid total protein in pediatric ascites.
     Clin Res Hepatol Gastroenterol. 2021;45:101549.
     PubMed     Abstract available
     
     
     
251. KARATAS E, Bouchecareilh M
     Alpha 1-Antitrypsin deficiency in liver explants in a Mexican cohort: A unique cohort to assess the role of heterozygous genotypes in liver disease.
     Clin Res Hepatol Gastroenterol. 2021;45:101538.
     PubMed    
     
     
     
252. DE MUNCK TJI, Verhaegh P, Lodewick T, Bakers F, et al
     Myosteatosis in nonalcoholic fatty liver disease: An exploratory study.
     Clin Res Hepatol Gastroenterol. 2021;45:101500.
     PubMed     Abstract available
     
     
     
253. DE VOS N, Van der Meulen J, Van Der Linden M, Claes K, et al
     Myxoid hepatocellular adenoma, a rare variant of hepatocellular adenoma with distinct imaging features: A case report with immunohistochemical and molecular analysis and literature review.
     Clin Res Hepatol Gastroenterol. 2021;45:101478.
     PubMed     Abstract available
     
     
     
254. LYKAVIERIS P, Bernard O, Jacquemin E
     Ursodeoxycholic acid therapy throughout pregnancy in women affected with chronic cholestasis of childhood: No evidence for teratogenicity.
     Clin Res Hepatol Gastroenterol. 2021;45:101472.
     PubMed    
     
     
     
255. RIVAS M, Aguiar T, Fernandes G, Lemes R, et al
     DNA methylation as a key epigenetic player for hepatoblastoma characterization.
     Clin Res Hepatol Gastroenterol. 2021;45:101684.
     PubMed     Abstract available
     
     
     
256. BOILLOT O, Cayot B, Guillaud O, Crozet-Chaussin J, et al
     Partial major hepatectomy with cyst fenestration for polycystic liver disease: Indications, short and long-term outcomes.
     Clin Res Hepatol Gastroenterol. 2021;45:101670.
     PubMed     Abstract available
     
     
     
257. KULKARNI AV, Tevethia HV, Arab JP, Candia R, et al
     Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
     Clin Res Hepatol Gastroenterol. 2021;45:101675.
     PubMed     Abstract available
     
     
     
258. ZAREBSKA I, Gzil A, Durslewicz J, Jaworski D, et al
     The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers.
     Clin Res Hepatol Gastroenterol. 2021;45:101664.
     PubMed     Abstract available
     
     
     April 2021
259. OZCELIK F
     Prognostic value of gamma-glutamyl transpeptidase in liver cirrhosis and hepatocellular cancer regardless of other parameters.
     Clin Res Hepatol Gastroenterol. 2021 Apr 27:101708.
     PubMed    
     
     
     
260. CARDOSO CC, Matiollo C, Pereira CHJ, Fonseca JS, et al
     B-cell compartment abnormalities are associated with ACLF and mortality in patients with liver cirrhosis.
     Clin Res Hepatol Gastroenterol. 2021 Apr 11:101698.
     PubMed     Abstract available
     
     
     March 2021
261. TORNAI D, Vitalis Z, Jonas A, Janka T, et al
     Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality.
     Clin Res Hepatol Gastroenterol. 2021;45:101579.
     PubMed     Abstract available
     
     
     
262. CAO X, Cao Z, Ou C, Zhang L, et al
     Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101583.
     PubMed     Abstract available
     
     
     
263. CORPECHOT C
     The revival of preemptive UDCA therapy in liver transplant recipients: Commentary to "UDCA decreases Incidence of Primary Biliary Cholangitis and Biliary Complications after Liver Transplant: A Meta-Analysis" by Pedersen et al., Liver Transplant, Nove
     Clin Res Hepatol Gastroenterol. 2021 Mar 13:101679.
     PubMed    
     
     
     
264. ALTIERI M, Seree O, Lobbedez T, Segol P, et al
     Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101514.
     PubMed     Abstract available
     
     
     
265. LANTHIER N, Starkel P, Dahlqvist G
     Frailty, sarcopenia and mortality in cirrhosis: what is the best assessment, how to interpret the data correctly and what interventions are possible?
     Clin Res Hepatol Gastroenterol. 2021 Mar 2:101661.
     PubMed     Abstract available
     
     
     
266. COUPIER A, Pioche M, Steer N, Zoulim F, et al
     An exceptional case of refractory variceal bleeding occurring during liver transplantation rescued with esophageal stent.
     Clin Res Hepatol Gastroenterol. 2021 Mar 2:101662.
     PubMed    
     
     
     
267. BLANC JF, Debaillon-Vesque A, Roth G, Barbare JC, et al
     Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI).
     Clin Res Hepatol Gastroenterol. 2021;45:101590.
     PubMed     Abstract available
     
     
     
268. TIAN J, Hu D
     LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival.
     Clin Res Hepatol Gastroenterol. 2021;45:101490.
     PubMed     Abstract available
     
     
     
269. SOBOTKA LA, Chen JL, Wellner MR
     Compression induced hepatic injury: an unusual case of abnormal liver function tests.
     Clin Res Hepatol Gastroenterol. 2021;45:101655.
     PubMed    
     
     
     
270. LIU Y, Wu H, Wang Z, Wu J, et al
     Integrated expression profiles of mRNA and miRNA in a gerbil model of fatty liver fibrosis treated with exenatide.
     Clin Res Hepatol Gastroenterol. 2021;45:101312.
     PubMed     Abstract available
     
     
     
271. SU Q, Wang H
     Long non-coding RNA 01559 mediates the malignant phenotypes of hepatocellular carcinoma cells through targeting miR-511.
     Clin Res Hepatol Gastroenterol. 2021;45:101648.
     PubMed     Abstract available
     
     
     
272. ROSSO C, Caviglia GP, Armandi A, Ribaldone DG, et al
     Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?
     Clin Res Hepatol Gastroenterol. 2021;45:101611.
     PubMed    
     
     
     
273. XIE Z, Wu Y, Liu S, Lai Y, et al
     LncRNA-SNHG7/miR-29b/DNMT3A axis affects activation, autophagy and proliferation of hepatic stellate cells in liver fibrosis.
     Clin Res Hepatol Gastroenterol. 2021;45:101469.
     PubMed     Abstract available
     
     
     
274. MAZZOLA A, Magro B, Perdigao F, Charlotte F, et al
     Acute liver failure and HELLP syndrome: A clinical case and literature review.
     Clin Res Hepatol Gastroenterol. 2021;45:101498.
     PubMed     Abstract available
     
     
     
275. SHEN X, Huang Y, Guo H, Peng H, et al
     Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus.
     Clin Res Hepatol Gastroenterol. 2021;45:101495.
     PubMed     Abstract available
     
     
     
276. XU X, Hou Z, Xu Y, Gu H, et al
     The dynamic of platelet count as a novel and valuable predictor for 90-day survival of hepatitis B virus-related acute-on-chronic liver failure patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101482.
     PubMed     Abstract available
     
     
     
277. CHEN C, Qiu H, Yao Y, Zhang Z, et al
     Comprehensive predictive factors for CalliSpheres(R) microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101460.
     PubMed     Abstract available
     
     
     
278. TURPIN A, de Baere T, Heurgue A, Le Malicot K, et al
     Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study.
     Clin Res Hepatol Gastroenterol. 2021;45:101464.
     PubMed     Abstract available
     
     
     February 2021
279. GAO Y, Liu H, Tang F, Zhang X, et al
     Efficacy and safety of anticoagulants in liver cirrhosis patients with portal vein thrombosis: A meta-analysis.
     Clin Res Hepatol Gastroenterol. 2021 Feb 15:101649.
     PubMed     Abstract available
     
     
     January 2021
280. ZHAO N, Liu X, Guo H, Zhao X, et al
     Interleukin-35: An emerging player in the progression of liver diseases.
     Clin Res Hepatol Gastroenterol. 2021;45:101518.
     PubMed     Abstract available
     
     
     
281. CHARPY F, Debourdeau A, Boivineau L, Meszaros M, et al
     Hepatic amyloidosis as a case of fatal fulminant liver failure.
     Clin Res Hepatol Gastroenterol. 2021;45:101506.
     PubMed    
     
     
     
282. BRAUNER C, Joveleviths D, Alvares-da-Silva MR
     Hepatotoxicity by methyl methacrylate.
     Clin Res Hepatol Gastroenterol. 2021;45:101513.
     PubMed    
     
     
     
283. THEVENOT T, Savale L, Sitbon O
     Portopulmonary hypertension: An unfolding story.
     Clin Res Hepatol Gastroenterol. 2021;45:101492.
     PubMed    
     
     
     
284. WANG J, Feng L, Zhang L
     Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis.
     Clin Res Hepatol Gastroenterol. 2021;45:101440.
     PubMed     Abstract available
     
     
     
285. LEMAITRE C, Thiebaut PA, Francois A, Michel P, et al
     An unexpected cause of heterogeneous liver.
     Clin Res Hepatol Gastroenterol. 2021;45:101444.
     PubMed    
     
     
     
286. KANG Y, Park S, Kim S, Han SJ, et al
     Validating the BAVENO VI criteria to identify low risk biliary atresia patients without endoscopy for esophageal varix.
     Clin Res Hepatol Gastroenterol. 2021;45:101437.
     PubMed     Abstract available
     
     
     
287. RAFFETTI E, Portolani N, Molfino S, Mentasti S, et al
     Is survival for hepatocellular carcinoma increasing? A population-based study on survival of hepatocellular carcinoma patients in the 1990s and 2000s.
     Clin Res Hepatol Gastroenterol. 2021;45:101433.
     PubMed     Abstract available
     
     
     
288. CHANG Y, He J, Xiang X, Li H, et al
     LUM is the hub gene of advanced fibrosis in nonalcoholic fatty liver disease patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101435.
     PubMed     Abstract available
     
     
     November 2020
289. HUANG C, Seah JJ, Tan CK, Kam JW, et al
     Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
     Clin Res Hepatol Gastroenterol. 2020 Nov 29:101528.
     PubMed     Abstract available
     
     
     August 2020
290. ELKRIEF L, Houssel-Debry P, Ackermann O, Franchi-Abella S, et al
     Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction.
     Clin Res Hepatol Gastroenterol. 2020 Aug 17. pii: S2210-7401(20)30091.
     PubMed     Abstract available
     
     
     July 2020
291. TRIPON S, Mayer P, Svab A, Habersetzer F, et al
     Intraabdominal urokinase in the treatment of loculated infected ascites in cirrhosis.
     Clin Res Hepatol Gastroenterol. 2020 Jul 9. pii: S2210-7401(20)30181.
     PubMed     Abstract available
     
     
     April 2020
292. ABERGEL A, Gasperment M, Nery FG, Buchard B, et al
     Extrahepatic portal vein obstruction (EHPVO) in cirrhosis.
     Clin Res Hepatol Gastroenterol. 2020 Apr 17. pii: S2210-7401(20)30089.
     PubMed    
     
     
     
293. JANKOWSKA I, Czubkowski P, Rokicki D, Lipinski P, et al
     Acute liver failure due to DGUOK deficiency-is liver transplantation justified?
     Clin Res Hepatol Gastroenterol. 2020 Apr 8. pii: S2210-7401(20)30082.
     PubMed     Abstract available
     
     
     March 2020
294. FELLI E, Baumert T, Pessaux P
     Is minimally invasive true anatomical HCC resection a future way to improve results in bridge or salvage liver transplantation?
     Clin Res Hepatol Gastroenterol. 2020 Mar 18. pii: S2210-7401(20)30049.
     PubMed    
     
     
     
295. MORANDEAU E, Rayer C, Jezequel C, Guyader D, et al
     Hepatic encephalopathy post liver transplantation.
     Clin Res Hepatol Gastroenterol. 2020 Mar 10. pii: S2210-7401(20)30039.
     PubMed    
     
     
     January 2020
296. PETA V, Zhu J, Lubman DM, Huguet S, et al
     Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.
     Clin Res Hepatol Gastroenterol. 2020 Jan 18. pii: S2210-7401(19)30272.
     PubMed     Abstract available
     
     
     
297. HEDJOUDJE A, Cervoni JP, Patry C, Chatot M, et al
     Takotsubo cardiomyopathy triggered by delirium tremens in a cirrhotic patient with acute-on-chronic liver failure: A case report.
     Clin Res Hepatol Gastroenterol. 2020 Jan 9. pii: S2210-7401(19)30262.
     PubMed     Abstract available
     
     
     November 2019
298. ALLAIRE M, Cadranel JF, Nguyen TTN, Garioud A, et al
     Management of infections in patients with cirrhosis in the context of increasing therapeutic resistance: A systematic review.
     Clin Res Hepatol Gastroenterol. 2019 Nov 6. pii: S2210-7401(19)30224.
     PubMed     Abstract available
     
     
     October 2019
299. ALLAIRE M, Walter A, Sutter O, Nahon P, et al
     TIPS for management of portal-hypertension-related complications in patients with cirrhosis.
     Clin Res Hepatol Gastroenterol. 2019 Oct 26. pii: S2210-7401(19)30217.
     PubMed     Abstract available
     
     
     June 2019
300. LIBERAL R, Gaspar R, Lopes S, Macedo G, et al
     Primary biliary cholangitis in patients with inflammatory bowel disease.
     Clin Res Hepatol Gastroenterol. 2019 Jun 3. pii: S2210-7401(19)30099.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.